Tags

Type your tag names separated by a space and hit enter

A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis.
J Investig Allergol Clin Immunol. 2013; 23(7):495-503.JI

Abstract

BACKGROUND AND OBJECTIVE

MP29-02 (Dymista), a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP), is significantly better than first-line therapy for the treatment of moderate-to-severe seasonal allergic rhinitis (SAR), and is well tolerated following 52 weeks of continuous use in chronic rhinitis. The aim of this study was to evaluate the long-term efficacy of MP29-02 versus FP in patients with chronic rhinitis.

PATIENTS AND METHODS

In total, 612 chronic rhinitis patients (perennial allergic rhinitis [PAR], n = 424; nonallergic rhinitis, n=188) aged 12 years or older were enrolled into this open-label, parallel-group study and randomized to MP29-02 (1 spray/nostril bid) or FP nasal spray (2 sprays/nostril qd) for 52 weeks. Efficacy was assessed by change from baseline in PM reflective total nasal symptom score (rTNSS), time to first achieve 100% PM rTNSS reduction from baseline, and percentage of symptom-free days in the total and PAR populations posthoc.

RESULTS

MP29-02 reduced patients' PM rTNSS from baseline significantly more than FP, from Day 1 up to and including week 28 (-2.88 vs -2.53; P = .0048), with treatment difference maintained for 52 weeks. Fluctuation in significance after week 28 might be explained, at least in part, by decreasing sample size, permitted according to ICH guidelines. By Day 1 almost twice as many MP29-02-patients were symptom free. After 1 month, 71.1% of MP29-02 patients experienced 100% rTNSS reduction (60.3% for FP), and did on a median of 9 days faster (P=.0024). Over 52 weeks MP29-02 patients experienced 8.4% more symptom-free days (P = .0005). These results were mirrored in the PAR subpopulation.

CONCLUSION

These results confirm MP29-02's wide therapeutic spectrum and assert its consistent superiority over an intranasal corticosteroid.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24654314

Citation

Price, D, et al. "A New Therapy (MP29-02) Is Effective for the Long-term Treatment of Chronic Rhinitis." Journal of Investigational Allergology & Clinical Immunology, vol. 23, no. 7, 2013, pp. 495-503.
Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495-503.
Price, D., Shah, S., Bhatia, S., Bachert, C., Berger, W., Bousquet, J., Carr, W., Hellings, P., Munzel, U., Scadding, G., & Lieberman, P. (2013). A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. Journal of Investigational Allergology & Clinical Immunology, 23(7), 495-503.
Price D, et al. A New Therapy (MP29-02) Is Effective for the Long-term Treatment of Chronic Rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495-503. PubMed PMID: 24654314.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. AU - Price,D, AU - Shah,S, AU - Bhatia,S, AU - Bachert,C, AU - Berger,W, AU - Bousquet,J, AU - Carr,W, AU - Hellings,P, AU - Munzel,U, AU - Scadding,G, AU - Lieberman,P, PY - 2014/3/25/entrez PY - 2013/1/1/pubmed PY - 2014/5/3/medline SP - 495 EP - 503 JF - Journal of investigational allergology & clinical immunology JO - J Investig Allergol Clin Immunol VL - 23 IS - 7 N2 - BACKGROUND AND OBJECTIVE: MP29-02 (Dymista), a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP), is significantly better than first-line therapy for the treatment of moderate-to-severe seasonal allergic rhinitis (SAR), and is well tolerated following 52 weeks of continuous use in chronic rhinitis. The aim of this study was to evaluate the long-term efficacy of MP29-02 versus FP in patients with chronic rhinitis. PATIENTS AND METHODS: In total, 612 chronic rhinitis patients (perennial allergic rhinitis [PAR], n = 424; nonallergic rhinitis, n=188) aged 12 years or older were enrolled into this open-label, parallel-group study and randomized to MP29-02 (1 spray/nostril bid) or FP nasal spray (2 sprays/nostril qd) for 52 weeks. Efficacy was assessed by change from baseline in PM reflective total nasal symptom score (rTNSS), time to first achieve 100% PM rTNSS reduction from baseline, and percentage of symptom-free days in the total and PAR populations posthoc. RESULTS: MP29-02 reduced patients' PM rTNSS from baseline significantly more than FP, from Day 1 up to and including week 28 (-2.88 vs -2.53; P = .0048), with treatment difference maintained for 52 weeks. Fluctuation in significance after week 28 might be explained, at least in part, by decreasing sample size, permitted according to ICH guidelines. By Day 1 almost twice as many MP29-02-patients were symptom free. After 1 month, 71.1% of MP29-02 patients experienced 100% rTNSS reduction (60.3% for FP), and did on a median of 9 days faster (P=.0024). Over 52 weeks MP29-02 patients experienced 8.4% more symptom-free days (P = .0005). These results were mirrored in the PAR subpopulation. CONCLUSION: These results confirm MP29-02's wide therapeutic spectrum and assert its consistent superiority over an intranasal corticosteroid. SN - 1018-9068 UR - https://www.unboundmedicine.com/medline/citation/24654314/A_new_therapy__MP29_02__is_effective_for_the_long_term_treatment_of_chronic_rhinitis_ L2 - http://www.jiaci.org/issues/vol23issue7/vol23issue07-7.htm DB - PRIME DP - Unbound Medicine ER -